STAT+: Q&A: Sen. Sanders on insulin costs and his committee’s generic drug kerfuffle
"Both [drugmakers and PBMs] share major responsibility for the outrageously high prices that we pay," Sen. Bernie Sanders said in an interview about this week's insulin hearing.
WASHINGTON — Wednesday’s Senate hearing on high costs for insulin “is not the end” of Sen. Bernie Sanders’ plans for drug pricing interrogations, he told STAT in an interview. But it will be a show.
The Vermont Independent is bringing executives from drugmakers Eli Lilly, Novo Nordisk, and Sanofi, along with pharmacy benefit managers Express Scripts, OptumRx, and CVS Health, to appear before the Senate Health, Education, Labor, and Pensions Committee this week.
What's Your Reaction?
